Current Treatment Options for Paroxysmal Nocturnal Hemoglobinuria
Author Information
Author(s): Julia J. Shi, Yusuf M. Ozcan, Carlos I. Ayala Santos, Hetalkumari Patel, Jamile Shammo, Taha Bat
Primary Institution: University of Texas Southwestern Medical Center
Conclusion
The review highlights the significant advancements in treatment options for paroxysmal nocturnal hemoglobinuria (PNH) since the approval of the first medication in 2007.
Supporting Evidence
- PNH is a rare blood disorder caused by mutations leading to the destruction of red blood cells.
- Eculizumab was the first treatment approved for PNH in 2007, and since then, many new options have emerged.
- Current treatments include eculizumab, ravulizumab, pegcetacoplan, and iptacopan, each with unique mechanisms and benefits.
Takeaway
Doctors have found better ways to help people with a rare blood disease called PNH, which makes their blood cells break down too quickly. New medicines can help these patients feel better and live longer.
Methodology
This is a critical review examining available medications for PNH, their effectiveness, and treatment considerations.
Limitations
The review does not address PNH clonal dynamics, disease presentation, or when to initiate treatment.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website